NCT06308094Recruiting
320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment strategies.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 6 Mar 2024
- Start date
- 10 Apr 2025
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Johns Hopkins University
- Diseases
- Atrial fibrillation
- NCT number
- NCT06308094
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 10 Apr 2025 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient with iodinated contrast administration for other reason 24 hours prior to investigational CT.
Other illness
- Known allergy to iodinated contrast media.
- Patients with heart transplantation.
- Presence of any other history or condition that the investigator feels would be problematic.
- Patients who have a heart pacemaker, metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, mechanical heart valves and prosthetics that contain metal.
Lab values
- Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula).
- Patients with a positive urine or serum pregnancy test will be excluded from this study.
Other
- Patients with polymorphic ventricular tachycardia (VT) or presenting in electrical storm.
- Patients with severe claustrophobia.
Who the study is looking for
- Patients must be at least 21 years old at the time of enrollment.
- Patients must be able to give informed consent.
- Patients with symptomatic paroxysmal/persistent atrial fibrillation (AF).
- Eligible patients must be determined to be suitable candidates for ablation to treat AF by their cardiologist and/or electrophysiologists regardless of this protocol.
- Patients are scheduled to have a pre-procedure cardiac CT upon the discretion of their electrophysiologists
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.